{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T23:34:32Z","timestamp":1791588872590,"version":"4.3.4"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,7]],"date-time":"2023-04-07T00:00:00Z","timestamp":1680825600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,7]],"date-time":"2023-04-07T00:00:00Z","timestamp":1680825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Genomics"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Secukinumab is a fully human IgG1\u03ba MoAb that selectively binds to IL-17A with high affinity, and it has been proven effective for the treatment of psoriasis. However, the immune response pathways and mechanisms during the treatment are still masked. Therefore, the current study was designed to investigate the potential immune response genes via bioinformatics approaches.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Gene expression data of severe plaque-type psoriasis was retrieved from the GEO database. Quantification of immune infiltration by ssGSEA and identification of differentially infiltrated immune cells were conducted to validate the treatment effect of secukinumab. After data processing, differentially expressed genes were identified between the treatment and untreated group. TC-seq was employed to analyze the trend of gene expression and clustering analysis. IL-17 therapeutic immune response genes were selected by taking the intersection of the genes inside the key cluster set and the MAD3-PSO geneset. Based on these therapeutic response genes, protein\u2013protein interaction networks were built for key hub gene selection. These hub genes would work as potential immune response genes, and be validated via an external dataset.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Enrichment scores calculated by ssGSEA illustrated that the immune infiltration level of T cells had a strong difference before and after medication, which validated the treatment effect of Secukinumab. 1525 genes that have significantly different expression patterns before and after treatment were extracted for further analysis, and the enrichment result shows that these genes have the function related to epidermal development, differentiation, and keratinocytes differentiation. After overlapping candidate genes with MAD3-PSO gene set, 695 genes were defined as anti-IL7A treatment immune response genes, which were mainly enriched in receptor signaling and IL-17 signaling pathways. Hub gene were pinpointed from the PPI network constructed by anti-IL7A treatment immune response genes, their expression pattern fits TC-seq gene expression pattern.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our study revealed the potential anti-IL7A treatment immune response genes, and the central hub genes, which may act critical roles in Secukinumab, induced immune response. This would open up a novel and effective avenue for the treatment of psoriasis.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12920-023-01507-w","type":"journal-article","created":{"date-parts":[[2023,4,7]],"date-time":"2023-04-07T15:02:50Z","timestamp":1680879770000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Identification immune response genes in psoriasis after treatment with secukinumab"],"prefix":"10.1186","volume":"16","author":[{"given":"Jing","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaomei","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningyu","family":"Mi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulin","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,7]]},"reference":[{"issue":"6","key":"1507_CR1","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1111\/jdv.12751","volume":"29","author":"C Paul","year":"2015","unstructured":"Paul C, Lacour JP, Tedremets L, Kreutzer K, Jazayeri S, Adams S, et al. Efficacy, safety and usability of secukinumab administration by autoinjector\/pen in psoriasis: a randomized, controlled trial (JUNCTURE). J Eur Acad Dermatol Venereol JEADV. 2015;29(6):1082\u201390.","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"issue":"2","key":"1507_CR2","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/bjd.13348","volume":"172","author":"A Blauvelt","year":"2015","unstructured":"Blauvelt A, Prinz JC, Gottlieb AB, Kingo K, Sofen H, Ruer-Mulard M, et al. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Dermatol. 2015;172(2):484\u201393.","journal-title":"Br J Dermatol"},{"issue":"4","key":"1507_CR3","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1056\/NEJMoa1314258","volume":"371","author":"RG Langley","year":"2014","unstructured":"Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CEM, Papp K, et al. Secukinumab in plaque psoriasis\u2013results of two phase 3 trials. N Engl J Med. 2014;371(4):326\u201338.","journal-title":"N Engl J Med"},{"issue":"14","key":"1507_CR4","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","volume":"373","author":"PJ Mease","year":"2015","unstructured":"Mease PJ, McInnes IB, Kirkham B, Kavanaugh A, Rahman P, van der Heijde D, et al. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med. 2015;373(14):1329\u201339.","journal-title":"N Engl J Med"},{"issue":"9999","key":"1507_CR5","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","volume":"386","author":"IB McInnes","year":"2015","unstructured":"McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Lond Engl. 2015;386(9999):1137\u201346.","journal-title":"Lancet Lond Engl"},{"issue":"26","key":"1507_CR6","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","volume":"373","author":"D Baeten","year":"2015","unstructured":"Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, et al. Secukinumab, an interleukin-17A inhibitor, ankylosing spondylitis. N Engl J Med. 2015;373(26):2534\u201348.","journal-title":"N Engl J Med"},{"issue":"3","key":"1507_CR7","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.jaad.2013.11.013","volume":"70","author":"TD Rachakonda","year":"2014","unstructured":"Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014;70(3):512\u20136.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1507_CR8","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1046\/j.1365-2230.2001.00832.x","volume":"26","author":"E Christophers","year":"2001","unstructured":"Christophers E. Psoriasis\u2013epidemiology and clinical spectrum. Clin Exp Dermatol. 2001;26(4):314\u201320.","journal-title":"Clin Exp Dermatol"},{"key":"1507_CR9","doi-asserted-by":"crossref","unstructured":"Feldman SR, Malakouti M, Koo JY. Social impact of the burden of psoriasis: effects on patients and practice. Dermatol Online J. 2014;20(8):13030\/qt48r4w8h2.","DOI":"10.5070\/D3208023523"},{"key":"1507_CR10","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1146\/annurev-immunol-032713-120225","volume":"32","author":"MA Lowes","year":"2014","unstructured":"Lowes MA, Su\u00e1rez-Fari\u00f1as M, Krueger JG. Immunology of psoriasis. Annu Rev Immunol. 2014;32:227\u201355.","journal-title":"Annu Rev Immunol"},{"issue":"3","key":"1507_CR11","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/jid.2010.340","volume":"131","author":"A Chiricozzi","year":"2011","unstructured":"Chiricozzi A, Guttman-Yassky E, Su\u00e1rez-Fari\u00f1as M, Nograles KE, Tian S, Cardinale I, et al. Integrative responses to IL-17 and TNF-\u03b1 in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol. 2011;131(3):677\u201387.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"1507_CR12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s13317-013-0057-4","volume":"5","author":"B Marinoni","year":"2014","unstructured":"Marinoni B, Ceribelli A, Massarotti MS, Selmi C. The Th17 axis in psoriatic disease: pathogenetic and therapeutic implications. Auto- Immun Highlights. 2014;5(1):9\u201319.","journal-title":"Auto- Immun Highlights"},{"issue":"1","key":"1507_CR13","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/jid.2012.194","volume":"133","author":"DA Martin","year":"2013","unstructured":"Martin DA, Towne JE, Kricorian G, Klekotka P, Gudjonsson JE, Krueger JG, et al. The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. J Invest Dermatol. 2013;133(1):17\u201326.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"1507_CR14","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/bjd.14034","volume":"174","author":"A Chiricozzi","year":"2016","unstructured":"Chiricozzi A, Su\u00e1rez-Fari\u00f1as M, Fuentes-Duculan J, Cueto I, Li K, Tian S, et al. Increased expression of interleukin-17 pathway genes in nonlesional skin of moderate-to-severe psoriasis vulgaris. Br J Dermatol. 2016;174(1):136\u201345.","journal-title":"Br J Dermatol"},{"issue":"12","key":"1507_CR15","doi-asserted-by":"publisher","first-page":"2990","DOI":"10.1038\/jid.2014.268","volume":"134","author":"CQF Wang","year":"2014","unstructured":"Wang CQF, Su\u00e1rez-Fari\u00f1as M, Nograles KE, Mimoso CA, Shrom D, Dow ER, et al. IL-17 induces inflammation-associated gene products in blood monocytes, and treatment with ixekizumab reduces their expression in psoriasis patient blood. J Invest Dermatol. 2014;134(12):2990\u20133.","journal-title":"J Invest Dermatol"},{"issue":"2","key":"1507_CR16","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/imm.12142","volume":"141","author":"BW Kirkham","year":"2014","unstructured":"Kirkham BW, Kavanaugh A, Reich K. Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis. Immunology. 2014;141(2):133\u201342.","journal-title":"Immunology"},{"issue":"3","key":"1507_CR17","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s12016-018-8702-3","volume":"55","author":"A Blauvelt","year":"2018","unstructured":"Blauvelt A, Chiricozzi A. The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clin Rev Allergy Immunol. 2018;55(3):379\u201390.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"6 Suppl 1","key":"1507_CR18","first-page":"S3","volume":"9","author":"JA Zeichner","year":"2016","unstructured":"Zeichner JA, Armstrong A. The role of IL-17 in the pathogenesis and treatment of psoriasis. J Clin Aesthetic Dermatol. 2016;9(6 Suppl 1):S3-6.","journal-title":"J Clin Aesthetic Dermatol"},{"issue":"1","key":"1507_CR19","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jaad.2016.08.008","volume":"76","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, Reich K, Tsai TF, Tyring S, Vanaclocha F, Kingo K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study. J Am Acad Dermatol. 2017;76(1):60-69.e9.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1507_CR20","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.jaad.2015.05.013","volume":"73","author":"D Tha\u00e7i","year":"2015","unstructured":"Tha\u00e7i D, Blauvelt A, Reich K, Tsai TF, Vanaclocha F, Kingo K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015;73(3):400\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1507_CR21","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1007\/s12325-017-0521-z","volume":"34","author":"S Adsit","year":"2017","unstructured":"Adsit S, Zaldivar ER, Sofen H, Dei-Cas I, Maldonado-Garc\u00eda C, Pe\u00f1aranda EO, et al. Secukinumab is efficacious and safe in hispanic patients with moderate-to-severe plaque psoriasis: pooled analysis of four phase 3 trials. Adv Ther. 2017;34(6):1327\u201339.","journal-title":"Adv Ther"},{"issue":"1","key":"1507_CR22","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1177\/2040622317738910","volume":"9","author":"J Frieder","year":"2018","unstructured":"Frieder J, Kivelevitch D, Menter A. Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis. Ther Adv Chronic Dis. 2018;9(1):5\u201321.","journal-title":"Ther Adv Chronic Dis"},{"issue":"9","key":"1507_CR23","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1111\/jdv.14878","volume":"32","author":"R Bissonnette","year":"2018","unstructured":"Bissonnette R, Luger T, Tha\u00e7i D, Toth D, Lacombe A, Xia S, et al. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study). J Eur Acad Dermatol Venereol JEADV. 2018;32(9):1507\u201314.","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"issue":"7269","key":"1507_CR24","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nature08460","volume":"462","author":"DA Barbie","year":"2009","unstructured":"Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 2009;462(7269):108\u201312.","journal-title":"Nature"},{"issue":"7","key":"1507_CR25","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.","journal-title":"Nucleic Acids Res"},{"key":"1507_CR26","doi-asserted-by":"crossref","unstructured":"Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z, et al. clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. Innov Camb Mass. 2021;2(3):100141.","DOI":"10.1016\/j.xinn.2021.100141"},{"issue":"22","key":"1507_CR27","doi-asserted-by":"publisher","first-page":"12110","DOI":"10.3390\/ijms222212110","volume":"22","author":"X Ma","year":"2021","unstructured":"Ma X, Liu B, Gong Z, Qu Z, Cai J. Phosphoproteomic comparison of four Eimeria tenella life cycle stages. Int J Mol Sci. 2021;22(22):12110.","journal-title":"Int J Mol Sci"},{"key":"1507_CR28","doi-asserted-by":"publisher","first-page":"7001","DOI":"10.1038\/ncomms8001","volume":"6","author":"LC Tsoi","year":"2015","unstructured":"Tsoi LC, Spain SL, Ellinghaus E, Stuart PE, Capon F, Knight J, et al. Enhanced meta-analysis and replication studies identify five new psoriasis susceptibility loci. Nat Commun. 2015;6:7001.","journal-title":"Nat Commun"},{"issue":"2","key":"1507_CR29","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/jdv.13854","volume":"31","author":"IM Michalek","year":"2017","unstructured":"Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol JEADV. 2017;31(2):205\u201312.","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"issue":"2","key":"1507_CR30","first-page":"187","volume":"17","author":"AS Paller","year":"2018","unstructured":"Paller AS, Singh R, Cloutier M, Gauthier-Loiselle M, Emond B, Gu\u00e9rin A, et al. Prevalence of psoriasis in children and adolescents in the United States: a claims-based analysis. J Drugs Dermatol JDD. 2018;17(2):187\u201394.","journal-title":"J Drugs Dermatol JDD"},{"key":"1507_CR31","doi-asserted-by":"crossref","unstructured":"Parisi R, Symmons DPM, Griffiths CEM, Ashcroft DM, Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377\u201385.","DOI":"10.1038\/jid.2012.339"},{"key":"1507_CR32","doi-asserted-by":"crossref","unstructured":"Lebwohl MG, Bachelez H, Barker J, Girolomoni G, Kavanaugh A, Langley RG, et al. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol. 2014;70(5):871\u2013881.","DOI":"10.1016\/j.jaad.2013.12.018"},{"issue":"3","key":"1507_CR33","doi-asserted-by":"publisher","first-page":"J314","DOI":"10.1016\/j.jaut.2009.12.001","volume":"34","author":"V Chandran","year":"2010","unstructured":"Chandran V, Raychaudhuri SP. Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun. 2010;34(3):J314-321.","journal-title":"J Autoimmun"},{"issue":"9","key":"1507_CR34","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/nri3707","volume":"14","author":"SL Gaffen","year":"2014","unstructured":"Gaffen SL, Jain R, Garg AV, Cua DJ. The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol. 2014;14(9):585\u2013600.","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"1507_CR35","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1080\/1744666X.2017.1292137","volume":"13","author":"L Puig","year":"2017","unstructured":"Puig L. The role of IL 23 in the treatment of psoriasis. Expert Rev Clin Immunol. 2017;13(6):525\u201334.","journal-title":"Expert Rev Clin Immunol"},{"issue":"3","key":"1507_CR36","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s40265-015-0359-0","volume":"75","author":"M Sanford","year":"2015","unstructured":"Sanford M, McKeage K. Secukinumab: first global approval. Drugs. 2015;75(3):329\u201338.","journal-title":"Drugs"},{"issue":"3","key":"1507_CR37","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.jaci.2017.07.004","volume":"140","author":"JE Hawkes","year":"2017","unstructured":"Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol. 2017;140(3):645\u201353.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"1507_CR38","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s40268-016-0152-x","volume":"17","author":"AVE de Carvalho","year":"2017","unstructured":"de Carvalho AVE, Duquia RP, Horta BL, Bonamigo RR. Efficacy of immunobiologic and small molecule inhibitor drugs for psoriasis: a systematic review and meta-analysis of randomized clinical trials. Drugs RD. 2017;17(1):29\u201351.","journal-title":"Drugs RD"},{"issue":"3","key":"1507_CR39","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s12016-017-8634-3","volume":"55","author":"WH Boehncke","year":"2018","unstructured":"Boehncke WH, Brembilla NC. Unmet needs in the field of psoriasis: pathogenesis and treatment. Clin Rev Allergy Immunol. 2018;55(3):295\u2013311.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"1","key":"1507_CR40","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.jaci.2019.09.029","volume":"145","author":"T Bertelsen","year":"2020","unstructured":"Bertelsen T, Ljungberg C, Litman T, Huppertz C, Hennze R, R\u00f8nholt K, et al. I\u03baB\u03b6 is a key player in the antipsoriatic effects of secukinumab. J Allergy Clin Immunol. 2020;145(1):379\u201390.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"1507_CR41","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12918-018-0671-x","volume":"13","author":"Y Zhao","year":"2019","unstructured":"Zhao Y, Jhamb D, Shu L, Arneson D, Rajpal DK, Yang X. Multi-omics integration reveals molecular networks and regulators of psoriasis. BMC Syst Biol. 2019;13(1):8.","journal-title":"BMC Syst Biol"},{"issue":"9","key":"1507_CR42","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/nri1689","volume":"5","author":"AM Bowcock","year":"2005","unstructured":"Bowcock AM, Krueger JG. Getting under the skin: the immunogenetics of psoriasis. Nat Rev Immunol. 2005;5(9):699\u2013711.","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"1507_CR43","doi-asserted-by":"publisher","first-page":"E1275","DOI":"10.3390\/ijms21041275","volume":"21","author":"M Furue","year":"2020","unstructured":"Furue M, Furue K, Tsuji G, Nakahara T. Interleukin-17A and keratinocytes in psoriasis. Int J Mol Sci. 2020;21(4):E1275.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"1507_CR44","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.jaci.2019.04.029","volume":"144","author":"JG Krueger","year":"2019","unstructured":"Krueger JG, Wharton KA, Schlitt T, Suprun M, Torene RI, Jiang X, et al. IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis. J Allergy Clin Immunol. 2019;144(3):750\u201363.","journal-title":"J Allergy Clin Immunol"}],"container-title":["BMC Medical Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-023-01507-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12920-023-01507-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-023-01507-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,7]],"date-time":"2023-04-07T15:04:40Z","timestamp":1680879880000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedgenomics.biomedcentral.com\/articles\/10.1186\/s12920-023-01507-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,7]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1507"],"URL":"https:\/\/doi.org\/10.1186\/s12920-023-01507-w","relation":{},"ISSN":["1755-8794"],"issn-type":[{"value":"1755-8794","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,7]]},"assertion":[{"value":"31 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"77"}}